Moustaqim-Barrette, Amina
Dhillon, Damon
Ng, Justin
Sundvick, Kristen
Ali, Farihah
Elton-Marshall, Tara
Leece, Pamela
Rittenbach, Katherine
Ferguson, Max
Buxton, Jane A.
Article History
Received: 19 December 2020
Accepted: 24 February 2021
First Online: 26 March 2021
Declarations
:
: This study uses secondary analysis of existing research data and is exempt from ethics review under Article 2.4 of the Canadian Tri-Council Policy Statement (TCPS2) for the ethical conduct of research involving humans and/or human biological materials [CitationRef removed].
: Authors JN, KS, DD, FA and TEM have no conflicts to declare. Author KR works for Alberta Health Services (AHS), the agency responsible for administering Alberta’s take-home naloxone program. Part of authors AMB, MF, and JB’s salary comes from the British Columbia Centre for Disease Control (BCCDC), the agency responsible for administering the British Columbia take-home naloxone program. Author PL is a co-investigator on another study with in-kind contribution of naloxone from Adapt Pharma. The company is not involved in the design or conduct of the study.